



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1638

In re: Application of SONG, et al.

Serial No.: 09/896,720

Examiner: KRUSE, DAVID H.

RECEIVED

Date Filed: June 29, 2001

Group: 1638


NOV 06 2002

For: UBIQUITIN LIGASE

TECH CENTER 1600/2900

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the
U.S. Postal Service as First Class mail in an envelope addressed to the
Commissioner for Patents, Washington, DC 20231 on
October 30, 2002.


Stanley A. Kim, Ph.D., Esq.

Reg. No. 42,730

TRANSMITTAL LETTER

Commissioner for Patents
Washington, DC 20231


Sir:

Please find enclosed for filing the following:

 Response; and One postcard.

Although no fee is believed due, please charge any underpayment to Deposit Account No. 50-0951. This letter is submitted in duplicate.


Respectfully submitted,



Gregory A. Nelson, Esq.
Registration No. 30,577
Stanley A. Kim, Ph.D., Esq.
Registration No. 42,730
AKERMAN SENTERFITT
222 Lakeview Avenue, Suite 400
West Palm Beach, FL 33401
Telephone: (561) 653-5000

Date: October 30, 2002

Docket No. 5853-173



#9/elec.
B
TECH CENTER 1600/2900
11/8/02
NOV 06 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of SONG, et al.

Application No.: 09/896,720 Examiner: KRUSE, DAVID H.

Date Filed: June 29, 2001 Group: 1638

For: UBIQUITIN LIGASE

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on October 30, 2002.

Reg. No. 42,730
Stanley A. Kim, Ph.D., Esq.

RESPONSE

Commissioner for Patents
Washington, DC 20231

Sir:

This response is in reply to the office action mailed October 1, 2002 (the "Office Action").

REMARKS

Election/Restriction

In the above-identified Office Action, the Examiner issued a restriction requirement and required election of one of the following groups under 35 U.S.C. § 121:

I: Claims 1-7, 19 and 20, drawn to a purified nucleic acid encoding a XB3 protein or an XB3-like protein, a vector comprising said nucleic acid, a cell comprising said nucleic acid and a method of modulating disease resistance in a plant cell or seed by transforming a plant cell with said nucleic acid, classified in class 536, subclass 23.6, for example.

II: Claims 8-13, drawn to a purified XB3-like protein and an antibody directed thereto, classified in class 530, subclass 370, for example.